Stefan D. Anker

Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.